Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline 2016 Market Review Research

Pune India, August 9, 2016 /MarketersMEDIA/ -- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline Companies Involved in Therapeutics Development are 4SC AG ,AB Science SA ,AbbVie Inc. ,Acetylon Pharmaceuticals, Inc. ,Actinium Pharmaceuticals, Inc. ,ADC Therapeutics Sarl ,Advenchen Laboratories, LLC ,Aeglea BioTherapeutics, Inc. ,Affichem SA ,Agios Pharmaceuticals, Inc. ,AIMM Therapeutics B.V. ,Akinion Pharmaceuticals AB ,Altor BioScience Corporation ,Amgen Inc. ,Antigen Express, Inc. ,Antisense Therapeutics Limited ,APIM Therapeutics AS ,Aprea AB ,arGEN-X BV ,Ariad Pharmaceuticals, Inc. ,Arno Therapeutics, Inc. ,Arog Pharmaceuticals, Inc. ,Array BioPharma Inc. ,Astellas Pharma Inc. ,Asterias Biotherapeutics, Inc. ,Astex Pharmaceuticals, Inc. ,AstraZeneca Plc ,Atara Biotherapeutics, Inc. ,Athenex, Inc. ,Aurigene Discovery Technologies Limited ,AVEO Pharmaceuticals, Inc. ,Bayer AG ,BCI Pharma ,Bellicum Pharmaceuticals, Inc. ,BerGenBio AS ,Bio-Cancer Treatment International Limited ,Bio-Path Holdings, Inc. ,BioInvent International AB ,BioLineRx, Ltd. ,BioSight Ltd. ,Blueprint Medicines Corporation ,Boehringer Ingelheim GmbH ,Boston Biomedical, Inc. ,Bristol-Myers Squibb Company ,Calithera Biosciences, Inc. ,Cancer Therapeutics CRC Pty Ltd ,Cantargia AB ,Cantex Pharmaceuticals, Inc. ,Cascadian Therapeutics Inc ,Celator Pharmaceuticals, Inc. ,Celgene Corporation ,Cellceutix Corporation ,Celldex Therapeutics, Inc. ,Cellectis S.A. ,Cellerant Therapeutics, Inc. ,Celyad SA ,CharlestonPharma LLC ,Constellation Pharmaceuticals, Inc. ,ConverGene, LLC ,Cornerstone Pharmaceuticals, Inc. ,Critical Outcome Technologies Inc. ,CrystalGenomics, Inc. ,CTI BioPharma Corp. ,Cyclacel Pharmaceuticals, Inc. ,Daiichi Sankyo Company, Limited ,DC Prime B.V. ,Debiopharm International SA ,Deciphera Pharmaceuticals, LLC ,DiNonA Inc. ,Eisai Co., Ltd. ,Eli Lilly and Company ,EntreChem, S.L. ,EpiZyme, Inc. ,Erytech Pharma SA ,Esperance Pharmaceuticals, Inc. ,Eureka Therapeutics, Inc. ,Exelixis, Inc. ,F. Hoffmann-La Roche Ltd. ,Fate Therapeutics, Inc. ,FORMA Therapeutics, Inc. ,Formula Pharmaceuticals, Inc. ,Fortress Biotech, Inc. ,Forty Seven Inc. ,Fujifilm Corporation ,Gadeta B.V. ,Galen Limited ,Gamida Cell Ltd. ,Genentech, Inc. ,Genoscience Pharma ,Genosco ,Genzyme Corporation ,Gilead Sciences, Inc. ,GlaxoSmithKline Plc ,GlycoMimetics, Inc. ,Golden Biotechnology Corp. ,H3 Biomedicine Inc. ,Hanmi Pharmaceuticals, Co. Ltd. ,HEC Pharm Co., Ltd. ,Huperion Sarl ,Hybrigenics S.A. ,Igenica Biotherapeutics, Inc. ,Ignyta, Inc. ,Immatics Biotechnologies GmbH ,Immune Pharmaceuticals Inc. ,Immune System Key Ltd. ,ImmunGene, Inc. ,ImmunoGen, Inc. ,Incyte Corporation ,Inflection Biosciences Limited ,Interprotein Corporation ,Jasco Pharmaceuticals, LLC. ,Jiangsu Hansoh Pharmaceutical Co., Ltd. ,Johnson & Johnson ,Juno Therapeutics Inc. ,JW Pharmaceutical Corporation ,Kainos Medicine, Inc. ,Karyopharm Therapeutics, Inc. ,Kiadis Pharma B.V. ,Kolltan Pharmaceuticals, Inc. ,Komipharm International Co., Ltd. ,Kyowa Hakko Kirin Co., Ltd. ,Lead Discovery Center GmbH ,Les Laboratoires Servier SAS ,MacroGenics, Inc. ,Mateon Therapeutics Inc ,MaxCyte, Inc. ,medac GmbH ,MediGene AG ,Medivation, Inc. ,MEI Pharma, Inc. ,Merck & Co., Inc. ,Merus B.V. ,Mesoblast Limited ,Millennium Pharmaceuticals, Inc. ,miRagen Therapeutics, Inc. ,Mirna Therapeutics, Inc. ,Moleculin Biotech, Inc. ,MolMed S.p.A. ,Nanovalent Pharmaceuticals Inc. ,NantKwest, Inc. ,Nemucore Medical Innovations, Inc. ,Nerviano Medical Sciences S.r.l. ,Neumedicines Inc. ,Novartis AG ,NuCana BioMed Limited ,Omeros Corporation ,OncoImmune, Inc. ,Onconova Therapeutics, Inc. ,Oncopeptides AB ,OncoTartis, Inc. ,OncoTherapy Science, Inc. ,Ono Pharmaceutical Co., Ltd. ,Otsuka Holdings Co., Ltd. ,Oxford BioTherapeutics Ltd ,Panther Biotechnology, Inc. ,Pfizer Inc. ,Pharma Mar, S.A. ,Pharmedartis GmbH ,Philogen S.p.A. ,Phylogica Limited ,Plexxikon Inc. ,Polaris Pharmaceuticals, Inc. ,Polyphor Ltd. ,Resverlogix Corp. ,Rich Pharmaceuticals, Inc. ,Sanofi ,Sareum Holdings Plc ,Seattle Genetics, Inc. ,Sellas Inc. ,Selvita S.A. ,Senhwa Biosciences, Inc. ,Shire Plc ,SialoTec GmbH ,Sigma-Tau S.p.A. ,SOM Innovation Biotech SL ,Sorrento Therapeutics, Inc. ,Stemline Therapeutics, Inc. ,Sumitomo Dainippon Pharma Co., Ltd. ,Sunesis Pharmaceuticals, Inc. ,Syndax Pharmaceuticals, Inc. ,SYNIMMUNE GmbH ,Synta Pharmaceuticals Corp. ,Syros Pharmaceuticals, Inc. ,TaiGen Biotechnology Co., Ltd. ,Takeda Pharmaceutical Company Limited ,Targazyme, Inc. ,TetraLogic Pharmaceuticals ,Teva Pharmaceutical Industries Ltd. ,Theravectys SA ,Toko Pharmaceutical Industries Co., Ltd. ,Tolero Pharmaceuticals, Inc. ,Tragara Pharmaceuticals, Inc. ,Trillium Therapeutics Inc. ,Verastem, Inc. ,Vichem Chemie Research Ltd. ,VioQuest Pharmaceuticals, Inc. ,Viralytics Ltd. ,Xencor, Inc. ,Xenetic Biosciences (UK) Limited ,ZIOPHARM Oncology, Inc.

The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects.

Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=655391

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline therapeutics constitutes close to 400 molecules. Out of which approximately 349 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 89, 76, 1, 8, 137, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 11, 20 and 10 molecules, respectively.

Complete research report of 1371 pages with TOC is available at http://www.rnrmarketresearch.com/acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-2016-market-report.html

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

- The report reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects

- The report assesses Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Website: http://www.rnrmarketresearch.com/

Release ID: 126931